PDCD1 and esophageal squamous cell carcinoma: Given the known temporal and spatial intratumoral heterogeneity that is a hallmark of advanced ESCC and its microenvironment26, CPS may be more likely than TPS to identify a greater proportion of patients who may benefit from anti-PD-1 therapy and was therefore used in the present trial for patient screening.